Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.68 |
| ▸ | AR | P10275 | 6/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.55 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.55 |
| ▸ | ABCB11 | O95342 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluocortolone SCHEMBL11518086 | 0.98 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL11333890 | 0.98 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL4644 | 0.98 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL3047399 | 0.98 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL11862489 | 0.98 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL13902941 | 0.98 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL19327147 | 0.98 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL21706397 | 0.98 | PGR (0.70) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL3690986 | 0.97 | PGR (0.67) | PGRARADRA1ACHRM1ADORA3 | |
| Fluocortolone SCHEMBL144059 | 0.97 | PGR (0.69) | PGRARADRA1ACHRM1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189348-A1 | NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS | CMPD LICENSING, LLC (US) | 2024-06-13 | — | — | US | disclosed |
| US-20240130983-A1 | COMPOUNDS FOR TREATING CORONAVIRUS INFECTION | NLC PHARMA LTD (IL) | 2024-04-25 | — | — | US | disclosed |
| US-20240100004-A9 | TOPICAL COMPOSITIONS AND METHODS OF FORMULATING SAME | CMPD LICENSING, LLC (US) | 2024-03-28 | — | — | US | disclosed |
| US-20240082152-A1 | NEBULIZATION FORMULATIONS FOR DELIVERY TO LOWER RESPIRATORY TRACT | CMPD Lincensing, LLC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240033305-A1 | COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY GUT BARRIER | FINCH THERAPEUTICS HOLDINGS LLC (US) | 2024-02-01 | — | — | US | disclosed |
| US-11826465-B2 | Nebulization formulations for delivery to lower respiratory tract | CMPD LICENSING, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230255913-A1 | TOPICAL COMPOSITIONS AND METHODS OF FORMULATING SAME | CMPD LICENSING, LLC (US) | 2023-08-17 | — | — | US | disclosed |
| US-11701426-B2 | Non-infective nasal symptom management compositions and methods | CMPD LICENSING, LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230135537-A1 | NEBULIZATION FORMULATIONS FOR DELIVERY TO LOWER RESPIRATORY TRACT | CMPD LICENSING, LLC (US) | 2023-05-04 | — | — | US | disclosed |
| US-11324694-B1 | Nebulization formulations for delivery to lower respiratory tract | CMPD LICENSING, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-20220047627-A1 | NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS | CMPD LICENSING, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20210386748-A1 | NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS | CMPD LICENSING, LLC (US) | 2021-12-16 | — | — | US | disclosed |
| US-20200179409-A1 | TOPICAL COMPOSITIONS AND METHODS OF FORMULATING THE SAME | CMPD LICENSING, LLC (US) | 2020-06-11 | — | — | US | disclosed |
| US-20200121795-A1 | NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS | CMPD LICENSING, LLC (US) | 2020-04-23 | — | — | US | disclosed |
| US-20200121696-A1 | NON-INFECTIVE NASAL SYMPTOM MANAGEMENT COMPOSITIONS AND METHODS | CMPD LICENSING, LLC (US) | 2020-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240033305-A1 | COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY GUT BARRIER | FABP2, SLC10A2, SI | PGR 4461/4885AR 4779/4885ADRA1A 3157/4885 |
| US-20240130983-A1 | COMPOUNDS FOR TREATING CORONAVIRUS INFECTION | SARS1, BECN1, PRSS1 | PGR 1731/4885AR 3363/4885ADRA1A 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.